EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03777384

Enrollment

Registered

2018-12-17

Start date

2018-10-12

Completion date

2026-12-01

Last updated

2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oropharyngeal Cancer

Keywords

oropharynx, head and neck cancer

Brief summary

A prospective, observational study evaluating the durability of local/regional control of previously published de-escalated radiotherapy protocols for patients with P16 positive oropharynx cancers who have minimal nicotine exposure who are not current uses (\< 10 pack year smoking history; \< 10 year history of any nicotine product \[electronic cigarette, chewing tobacco\]). Quality of Life measures will also be collected.

Detailed description

This is a prospective, single-site, observational study in head and neck cancer participants. The purpose of this study is to provide a systematic platform to analyze, interpret, and track radiation dose de-escalation therapy and associated participant outcomes from treatments identified by these results. Participants will be asked to complete quality of life questionnaires at regular time points before, during, and after treatment.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Histologic confirmation of tumor of the oropharynx * Radiation therapy (de-escalated head and neck irradiation) decision has been made * Human Papilloma Virus (HPV) associated cancer as determined by positive p16 immunohistochemistry * HPV positivity is defined by p16 IHC staining of \> 70% of tumor cells (strong and diffuse nuclear and cytoplasmic staining) * For cases that are indeterminate or if p16 testing cannot be accurately performed, HPV positivity can be confirmed by high-risk HPV DNA Testing which covers the following HPV subtypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 * \< 10 pack year smoking history OR \< 10 year nicotine use history * No current tobacco/nicotine use (including electronic cigarettes and chewing tobacco) * T1-T3, N0-N2 (AJCC8) requiring definitive therapy greater than surgery alone * Ability to provide informed written consent * Willingness to return to Sanford Cancer Center for follow-up * Life expectancy \> 12 weeks * ECOG performance status \< 3 (Appendix B) * Adequate organ function for chemotherapy and radiotherapy

Exclusion criteria

* Any of the following because the inclusion criteria require delivery of radiotherapy and chemotherapy which is known to be genotoxic, and is associated with mutagenic and teratogenic effects: pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception. * Prior head and neck radiotherapy * Any factor precluding safe delivery of chemotherapy

Design outcomes

Primary

Measure	Time frame	Description
The durability of local disease control of de-escalated radiotherapy protocols in the community cancer center setting.	End of treatment to 5 years after end of treatment	Number of participants who remain disease free from the end of treatment to 5 years after treatment.

Countries

United States

Contacts

STUDY_CHAIRMiran Blanchard, MD

Sanford Health

Outcome results